Cargando…
Rethinking the red wolf disease: does Protein S suppress systemic lupus erythematosus clinical activity?
In systemic lupus erythematosus, the forces responsible for disease initiation and self-perpetuation in these clinically heterogeneous populations remain poorly understood. Recent studies of the TAM (Tyro3, Axl and MerTK) family of receptor tyrosine kinases may lead to a better understanding of the...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991027/ https://www.ncbi.nlm.nih.gov/pubmed/21067626 http://dx.doi.org/10.1186/ar3162 |
_version_ | 1782192546658648064 |
---|---|
author | Silverman, Gregg J |
author_facet | Silverman, Gregg J |
author_sort | Silverman, Gregg J |
collection | PubMed |
description | In systemic lupus erythematosus, the forces responsible for disease initiation and self-perpetuation in these clinically heterogeneous populations remain poorly understood. Recent studies of the TAM (Tyro3, Axl and MerTK) family of receptor tyrosine kinases may lead to a better understanding of the fundamental control system responsible for the clearance of apoptotic cells and the regulation of inflammation. In a recent report, serum levels of the TAM ligand, Protein S, was found to correlate with certain disease manifestations and with C3 and C4 levels. Protein S levels could provide a quantitative clinical biomarker but it remains to be determined whether this factor directly affects disease activity. |
format | Text |
id | pubmed-2991027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29910272011-04-27 Rethinking the red wolf disease: does Protein S suppress systemic lupus erythematosus clinical activity? Silverman, Gregg J Arthritis Res Ther Editorial In systemic lupus erythematosus, the forces responsible for disease initiation and self-perpetuation in these clinically heterogeneous populations remain poorly understood. Recent studies of the TAM (Tyro3, Axl and MerTK) family of receptor tyrosine kinases may lead to a better understanding of the fundamental control system responsible for the clearance of apoptotic cells and the regulation of inflammation. In a recent report, serum levels of the TAM ligand, Protein S, was found to correlate with certain disease manifestations and with C3 and C4 levels. Protein S levels could provide a quantitative clinical biomarker but it remains to be determined whether this factor directly affects disease activity. BioMed Central 2010 2010-10-27 /pmc/articles/PMC2991027/ /pubmed/21067626 http://dx.doi.org/10.1186/ar3162 Text en Copyright ©2010 BioMed Central Ltd |
spellingShingle | Editorial Silverman, Gregg J Rethinking the red wolf disease: does Protein S suppress systemic lupus erythematosus clinical activity? |
title | Rethinking the red wolf disease: does Protein S suppress systemic lupus erythematosus clinical activity? |
title_full | Rethinking the red wolf disease: does Protein S suppress systemic lupus erythematosus clinical activity? |
title_fullStr | Rethinking the red wolf disease: does Protein S suppress systemic lupus erythematosus clinical activity? |
title_full_unstemmed | Rethinking the red wolf disease: does Protein S suppress systemic lupus erythematosus clinical activity? |
title_short | Rethinking the red wolf disease: does Protein S suppress systemic lupus erythematosus clinical activity? |
title_sort | rethinking the red wolf disease: does protein s suppress systemic lupus erythematosus clinical activity? |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991027/ https://www.ncbi.nlm.nih.gov/pubmed/21067626 http://dx.doi.org/10.1186/ar3162 |
work_keys_str_mv | AT silvermangreggj rethinkingtheredwolfdiseasedoesproteinssuppresssystemiclupuserythematosusclinicalactivity |